BioPharm International-02-01-2015

February 06, 2015

Changes in the country’s political landscape may affect the pharmaceutical industry market in the future.

February 01, 2015

They may not be glamorous, but buffers play an important role in biopharma manufacturing.

February 01, 2015

Protos 3 is Synbiosis’ automated colony counter and chromogenic identification system.

February 01, 2015

Watson-Marlow’s 120 cased peristaltic pumps are designed for single-use systems that require no contamination.

February 01, 2015

As ADCs move through the drug-development process, different analytical methods are often required.

February 01, 2015

Initiatives to speed drug development must pass Congress and special interest groups.

February 01, 2015

Evaluating the assembly design process, manufacture, and use helps mitigate risk.

February 01, 2015

Manufacturers face new rules for tracing drugs through the supply chain and compounders face stricter standards.

February 01, 2015

Market forces may limit the success of CMOs.

February 01, 2015

Investors are lining up for the biosimilars market as patents reach expiration and regulatory pathways are defined.

February 01, 2015

Understanding the influence of change events on product performance is a necessity to routine drug development, transfer, and validation.

February 01, 2015

EMA is under pressure to exert even tighter standards on biosimilars being marketed in Europe.

February 01, 2015

The use of commercially available media to achieve high titer in early process development is discussed.

February 01, 2015

The author discusses the various ways in which a quality-by-design program can enhance the extractable and leachable assessment of a drug product.

February 01, 2015

Click the title above to open the BioPharm International February 2015 issue in an interactive PDF format.